Findell Capital Management LLC Acquires New Holdings in ADMA Biologics Inc $ADMA

Findell Capital Management LLC purchased a new position in ADMA Biologics Inc (NASDAQ:ADMA) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 300,000 shares of the biotechnology company’s stock, valued at approximately $5,472,000. ADMA Biologics comprises approximately 1.6% of Findell Capital Management LLC’s holdings, making the stock its 13th largest holding.

Several other institutional investors have also added to or reduced their stakes in the business. State Street Corp boosted its holdings in ADMA Biologics by 0.3% in the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock worth $248,014,000 after acquiring an additional 35,614 shares in the last quarter. Sachem Head Capital Management LP boosted its holdings in ADMA Biologics by 27.0% in the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock worth $207,480,000 after acquiring an additional 2,415,000 shares in the last quarter. Westfield Capital Management Co. LP boosted its holdings in ADMA Biologics by 36.9% in the fourth quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock worth $127,551,000 after acquiring an additional 1,886,105 shares in the last quarter. Capital Research Global Investors boosted its holdings in ADMA Biologics by 104.0% in the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after acquiring an additional 3,383,559 shares in the last quarter. Finally, Nuveen LLC boosted its holdings in ADMA Biologics by 3.5% in the fourth quarter. Nuveen LLC now owns 5,926,390 shares of the biotechnology company’s stock worth $108,097,000 after acquiring an additional 202,245 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Trading Down 1.9%

ADMA Biologics stock opened at $8.42 on Thursday. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51. ADMA Biologics Inc has a 52 week low of $7.21 and a 52 week high of $20.46. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of 12.38 and a beta of 0.72. The stock has a 50-day moving average price of $9.13 and a 200 day moving average price of $13.90.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, hitting analysts’ consensus estimates of $0.19. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The firm had revenue of $114.49 million during the quarter, compared to the consensus estimate of $139.98 million. During the same quarter in the previous year, the company posted $0.11 earnings per share. The company’s revenue was down .3% compared to the same quarter last year. Sell-side analysts anticipate that ADMA Biologics Inc will post 0.82 EPS for the current year.

Insider Activity at ADMA Biologics

In other news, Director Jerrold B. Grossman bought 12,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $8.01 per share, with a total value of $100,125.00. Following the completion of the acquisition, the director directly owned 513,884 shares of the company’s stock, valued at $4,116,210.84. This trade represents a 2.49% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

ADMA has been the subject of several recent analyst reports. Mizuho lowered their price target on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Wall Street Zen downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Raymond James Financial initiated coverage on ADMA Biologics in a report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price target for the company. Canaccord Genuity Group lowered their price target on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $19.67.

ADMA Biologics News Roundup

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: No meaningful positive company-specific catalysts were announced in the provided news flow.
• Neutral Sentiment: Multiple law firms said investors can seek lead-plaintiff status, with an important deadline of August 10, 2026, but these notices are largely procedural and do not change the underlying allegations. Article Title
• Negative Sentiment: Several class-action lawsuits were filed or publicized against ADMA Biologics, Inc. for alleged securities fraud tied to revenue recognition and internal control issues, creating a significant legal risk overhang. Article Title
• Negative Sentiment: Some allegations specifically reference channel stuffing and an undisclosed related-party distributor, which could raise concerns about the quality of ADMA’s reported sales and controls. Article Title

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.